A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

11837

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection, COVID-19

Interventions

BIOLOGICAL: Biological/Vaccine: BNT162b2 10mcg
BIOLOGICAL: BNT162b2 20mcg
BIOLOGICAL: BNT162b2 30mcg
OTHER: Placebo
BIOLOGICAL: Biological/Vaccine: BNT162b2 3mcg

Sponsor

BioNTech SE

Collaborators

[object Object]